VEGFA and renal cell carcinoma: This review aims to determine whether neoadjuvant systemic therapy (VEGF-TKI, IO, or IO+TKI) increases the feasibility of PN and improves clinical outcomes in adults with high-complexity or locally advanced non-metastatic RCC.